螺旋镍钛支架髂支覆膜支架上市后注册研究最终结果
该前瞻性多中心上市后注册研究评估了Zenith Spiral-Z髂支覆膜支架在599例腹主动脉或主髂动脉瘤腔内修复患者中的临床结局。结果显示髂支闭塞率2%,肢体相关再干预率2%,30天死亡率1.7%,1年累积死亡率6.2%,支架通畅性良好且再干预少见。
要点
- 髂支闭塞发生率为2%(11/599),其中7例接受再干预。
- 肢体相关再干预共13例(2%),包括7例闭塞和8例非闭塞原因。
- 30天死亡率为1.7%,1年累积死亡率为6.2%,无主动脉破裂。
核心结论
- Spiral-Z髂支覆膜支架在常规临床实践中表现出优异的通畅性和较低的肢体相关再干预需求。
研究设计与样本
- 前瞻性、多中心上市后注册研究,计划纳入最多600例患者,实际纳入599例,来自美国和加拿大最多30个研究中心。
- 患者接受腹主动脉或主髂动脉瘤腔内修复,平均年龄74±8岁,87%为男性,26%为主髂动脉瘤。
- 短期数据在1至6个月收集,长期数据在12个月收集,平均随访11±6个月。
主要发现
- 髂支闭塞发生在11/599例(2%),其中3例在30天内,8例在30天后,均为单侧,且所有闭塞患者术中均未接受髂动脉辅助操作。
- 其他肢体相关再干预8例,原因包括非闭塞性扭结、压迫或血栓(6例在30天内,3例在30天后)。
- 共13例患者(2%)接受了15次肢体相关再干预(7次针对闭塞,8次针对非闭塞原因)。
- 1例患者在12个月随访时发现右侧髂支远端I型内漏和器械移位(>10 mm)。
- 平均随访11±6个月内未报告其他肢体相关内漏、移位、组件分离或支架断裂。
关键数值与推荐
- 髂动脉平均内径(左右侧)为9±3 mm。
- 左侧髂动脉中度/重度闭塞性疾病、钙化和血管扭曲分别占14%、25%和36%;右侧分别占15%、25%和34%。
- 术中髂动脉辅助操作(髂动脉血管成形术和/或支架置入)在112例患者(19%)中进行,其中52例为双侧。
临床怎么用
- Spiral-Z髂支覆膜支架在包括扭曲、钙化等复杂髂动脉解剖的常规临床实践中表现出良好的通畅性和较低的再干预率。
- 术后需关注肢体相关并发症,如闭塞、扭结、压迫等,尤其对于未接受术中髂动脉辅助操作的患者。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate clinical outcomes from a postmarket registry of the Zenith Spiral-Z abdominal aortic aneurysm iliac leg graft with a continuous, spiral nitinol stent that was designed for improved conformability, kink, and migration resistance. METHODS: This prospective, multicenter registry was designed to evaluate physician-reported outcomes of the Spiral-Z leg graft in up to 600 patients who underwent endovascular repair of abdominal aortic or aortoiliac aneurysms at up to 30 investigative sites in the United States and Canada. Study outcomes were focused on iliac limb occlusion, limb-related reintervention, limb-related endoleak, component separation, and device integrity. Short-term data were collected during an interval of 1 to 6 months, with longer term data collected at 12 months. RESULTS: Between March 2012 and March 2015, 599 patients (mean age 74 ± 8 years; 87% male; 26% with aortoiliac aneurysm) were treated, with Spiral-Z iliac leg grafts placed in 564 left iliac arteries and 559 right iliac arteries. The mean iliac inner diameters (both left and right) were 9 ± 3 mm; moderate/severe occlusive disease, calcification, and vessel tortuosity were present in 14%, 25%, and 36% and 15%, 25%, and 34% of the left and right iliac arteries, respectively. Iliac artery adjunctive procedures (iliac artery angioplasty and/or stent placement) were performed intraoperatively in 112 patients (19%; bilateral in 52 patients). Mortality within 30 days was 1.7% (10/599); cumulative mortality at 1 year was 6.2% (37/599). There were no aortic ruptures and only one open conversion (0.2%). Limb occlusions occurred in 11 of 599 patients (2%; 3 within 30 days and 8 after 30 days, all unilateral, none had received procedural iliac artery adjuncts at implantation); of these, 7 patients underwent reinterventions. Other limb-related reinterventions were performed on eight patients for nonocclusive kink, compression, or thrombus (six within 30 days and three after 30 days). In total, 13 patients (2%) underwent 15 limb-related reinterventions (7 for occlusions and 8 for nonocclusive causes). In one patient, a distal type I endoleak and device migration (>10 mm) involving a right iliac leg was noted at the 12-month follow-up visit. No other limb-related endoleak, migration, component separation, or stent fracture was reported during a mean follow-up of 11 ± 6 months. CONCLUSIONS: The Spiral-Z leg graft demonstrated excellent patency and required infrequent limb-related reinterventions in routine clinical care in a postmarket registry.
引用
- Lindsay T, Jazaeri O, Sherman SM, et al. Final results from a postmarket registry of an iliac leg graft with a continuous, spiral nitinol stent. J Vasc Surg. 2020. PMID: 31964568. doi:10.1016/j.jvs.2019.10.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。